ProPhase, based in Garden City, NY, recently announced a Memorandum of Understanding (MOU) between ProPhase Precision Medicine Inc. and affiliates of Nebula Genomics and G42 Healthcare in the Gulf emirate.
Utilization of genome data
The MOU covers genomic sequencing, artificial intelligence and sharing insights from genomic data. The companies also have a tentative plan to “synergize” each of their genomic sequencing capabilities.
G42 Healthcare is part of Abu Dhabi-based Group 42 (G42), which bills itself as “a leading AI and cloud computing company dedicated to the development and implementation of end-to-end and scalable AI solutions.”
The company has reportedly launched a $10 billion fund to invest in late-stage technology companies. G42 CEO Peng Xiao, who was educated in Hawaii and Washington DC, is also on the board of Yahsat, a satellite communications company in the United Arab Emirates.
“G42 Healthcare enables the world’s largest and most comprehensive population genomics initiative – the Emirati Genome Program, which aims to shift the traditional ecosystem from medical care to preventive healthcare for the citizens of the UAE, making G42 Healthcare an ideal strategic relationship for ProPhase. We are looking to strengthen our next-generation sequencing capabilities and build a new state-of-the-art genomic our sequencing equipment.” said Ted Karkus, CEO of ProPhase Lab.
Dr. George Church, professor of genetics at Harvard Medical School and founder of Nebula Genomics, said: “As an active advisor to both ProPhase Labs and G42, I am excited that this collaboration will bring together two organizations that are leaders in next-generation sequencing.”
ProPhase Labs has a diagnostic laboratory that also performs rapid COVID-19 testing, as well as a dietary supplement contract manufacturing facility and distributes TK supplements for men’s sexual and prostate health.